INHIBRX BIOSCIENCES, INC. (INBX) Current Ratio
- Current ratio · latest quarter: Value 5.07×; Formula and calculation Current assets / current liabilities..
Current ratio
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Current ratio · latest quarter | 5.07× | Current assets / current liabilities. $142.21M ÷ $28.06M ≈ 5.07× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Current assets | 142.21M USD | Assets, Current |
| Current obligations | 28.06M USD | Liabilities, Current |
| Cash and equivalents | 133.34M USD | Cash and Cash Equivalents, at Carrying Value |
| Short-term securities | (m) | |
| Customer receivables | (m) | |
| Inventory | (m) | |
| Payables | 9.80M USD | Accounts Payable, Current |
| Borrowing debt due within one year | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Current assets (USD) | Current obligations (USD) | Cash and equivalents (USD) | Short-term securities (USD) | Customer receivables (USD) | Inventory (USD) | Payables (USD) | Borrowing debt due within one year (USD) | Current ratio |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $142.21M | $28.06M | $133.34M | (m) | (m) | (m) | $9.80M | (m) | 5.07× |
| 2026-03-31 | $171.34M | $26.51M | $161.66M | (m) | (m) | (m) | $8.76M | (m) | 6.46× |
| 2025-12-31 | $132.83M | $33.80M | $124.22M | (m) | (m) | (m) | $5.94M | (m) | 3.93× |
| 2025-09-30 | $161.42M | $35.98M | $153.09M | (m) | (m) | (m) | $6.77M | (m) | 4.49× |
| 2025-06-30 | $193.96M | $38.94M | $186.57M | (m) | (m) | (m) | $8.29M | (m) | 4.98× |
| 2025-03-31 | $223.39M | $43.64M | $216.52M | (m) | (m) | (m) | $8.89M | (m) | 5.12× |
| 2024-12-31 | $160.40M | $40.73M | $152.60M | (m) | (m) | (m) | $9.24M | (m) | 3.94× |
| 2024-09-30 | $207.45M | $44.09M | $196.33M | (m) | (m) | (m) | $12.37M | (m) | 4.70× |
| 2024-06-30 | $242.06M | $39.05M | $226.86M | (m) | (m) | (m) | $13.02M | (m) | 6.20× |
| 2023-12-31 | $295.36M | $56.31M | $277.92M | (m) | (m) | (m) | $10.95M | (m) | 5.25× |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |